Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 20, Issue 2, Pages (February 2013)

Similar presentations


Presentation on theme: "Volume 20, Issue 2, Pages (February 2013)"— Presentation transcript:

1 Volume 20, Issue 2, Pages 142-143 (February 2013)
Rheostat-ing Mitosis  Patrick A. Eyers  Chemistry & Biology  Volume 20, Issue 2, Pages (February 2013) DOI: /j.chembiol Copyright © 2013 Elsevier Ltd Terms and Conditions

2 Figure 1 Arkin-1 Is a Target-Validated Fungal Aurora Kinase Inhibitor
(A) Chemical structures of VX-680 (Tozasertib) and Arkin-1, with prominent chemical groups shaded in blue. The piperazine group of VX-680 (blue) lies adjacent to G160 in the co-crystal structure with human Aurora B, and mutation to bulkier amino acids induces drug-resistance, presumably due to steric hindrance (Scutt et al., 2009). Based on this model, the equivalent G172 residue in Ark1 is likely to accommodate the N-7 pyridin-2-yl extension to the pyrrolopyrimidine ring of Arkin-1 (blue), and mutation to larger amino acids should induce phenotypic resistance in Aurora kinases to Arkin-1 and related compounds (Kawashima et al., 2013; Moriarty et al., 2006). (B) Alignment of amino acids in the ATP-binding site of fission yeast (Sp), human (Hs) and baker’s yeast (Sc) Aurora kinases. Four key amino acids make up the malleable resistance tetrad, corresponding to the four residues labeled in the human Aurora B and VX-680 cocrystal structure, which is derived from published coordinates (Protein Data Bank ID code 4AF3). Chemistry & Biology  , DOI: ( /j.chembiol ) Copyright © 2013 Elsevier Ltd Terms and Conditions


Download ppt "Volume 20, Issue 2, Pages (February 2013)"

Similar presentations


Ads by Google